Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Repurchased
Ratios

Ligand Pharmaceuticals (LGND) Long-Term Debt Issuances (2018 - 2022)

Ligand Pharmaceuticals' Long-Term Debt Issuances history spans 6 years, with the latest figure at $202000.0 for Q3 2022.

  • For Q3 2022, Long-Term Debt Issuances fell 90.3% year-over-year to $202000.0; the TTM value through Dec 2024 reached $202000.0, changed 0.0%, while the annual FY2025 figure was $460.0 million, N/A changed from the prior year.
  • Long-Term Debt Issuances for Q3 2022 was $202000.0 at Ligand Pharmaceuticals, down from $2.1 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $387.4 million in Q4 2018 and bottomed at -$697.9 million in Q3 2018.
  • The 4-year median for Long-Term Debt Issuances is $7.2 million (2019), against an average of -$46.5 million.
  • The largest annual shift saw Long-Term Debt Issuances skyrocketed 101.78% in 2019 before it tumbled 90.3% in 2022.
  • A 4-year view of Long-Term Debt Issuances shows it stood at $387.4 million in 2018, then plummeted by 96.8% to $12.4 million in 2019, then crashed by 83.2% to $2.1 million in 2021, then tumbled by 90.3% to $202000.0 in 2022.
  • Per Business Quant, the three most recent readings for LGND's Long-Term Debt Issuances are $202000.0 (Q3 2022), $2.1 million (Q3 2021), and $16.9 million (Q1 2021).